Summary
Highlights
The webinar begins by introducing the topic of regulatory documents for clinical research clinics, mentioning a previous popular animation video. It highlights that while specific documents may vary internationally, the underlying processes remain consistent. The 1572 Form is discussed as a crucial document, essentially a contract with the FDA, making the Principal Investigator (PI) responsible for the study's overall conduct.
The 1572 (Statement of Investigator) is detailed, covering its contents such as the names and addresses of PIs, labs, IRBs, sub-investigators, and protocols. It's explained as the PI's promise to the FDA regarding their liability. Financial Disclosure Forms (FDFs) are also covered as startup regulatory documents, requiring individuals involved in Box 6 of the 1572 to declare any financial interest in the sponsoring company, with specific thresholds varying by sponsor.
The protocol and its signature page are introduced as key startup documents. While training on the protocol isn't required until the Site Initiation Visit (SIV), the document must be signed. The Investigator Brochure (IB) contains all known data about the study drug and should be filed, even if rarely read by most. It's crucial for identifying serious adverse events (SAEs).
Startup regulatory includes credentials like CVs (current and signed, typically renewed every two years), GCP certificates (now often every two or three years, not annually as before), and IATA certificates. IATA (International Air Transport Association) certification is essential for staff shipping biological samples, particularly involving dry ice, to avoid significant penalties.
IRB approvals are critical for both startup and maintenance. Sites must obtain initial IRB approval for a study and annually renew it. Failure to renew can lead to protocol deviations for any patient activities conducted while IRB approval is lapsed. The discussion touches on distinctions between central and local IRBs and who is responsible for submissions.
The 1572 requires updates whenever there are changes to the PI, sub-investigators, addresses, labs, or IRB. Any changes to personnel listed on Box 6 of the 1572, including additions or removals of sub-investigators or coordinators, necessitate updating the 1572 and triggering new FDFs for new personnel. This emphasizes the dynamic nature of these documents throughout a study.
The delegation log, which details responsibilities for each task, must be completed before site initiation. Training logs document all staff training. It's emphasized that sites often under-document training, despite its importance. Training can be triggered by protocol amendments, performance issues, or corrective and preventive action plans (CAPAs). Anyone on the delegation log needs documented training.
For investigational products (IPs), key documents include order forms, shipping documents, kits received/dispensed logs (IP accountability logs), and temperature logs. These are filed in the regulatory binder or source documents. Other maintenance logs include screening and enrollment logs, which track subject IDs, initials, and dates of birth, and informed consent logs, which are frequently neglected reminders.
Safety reports (Suspected Unexpected Serious Adverse Reactions - SUSARs) are crucial. When an SAE is suspected to be related to the IP and is unexpected (not in the IB), a SUSAR report is distributed to all sites. PIs must acknowledge receipt by signing and dating these reports. Correspondence from the IRB, CRO, monitors, and sponsors, including printed emails and follow-up letters with action items, must also be filed and signed by the PI.
CLIA waivers or certificates are required for all sites, even those using central labs. These are site-specific and overseen by federal and state regulations. The reporting of protocol deviations to the IRB is also discussed, with advice to err on the side of caution and report all deviations, or at least document communication with the IRB if they deem it non-reportable via email.
The webinar concludes by addressing audience questions, including inquiries about medical device regulatory documents (clarifying that site-level regulatory is similar across product types, while sponsor-level pathways differ). The hosts also announce plans for a future 'unconference' in Orlando in September, focusing on providing actionable value for attendees.